Spojené štáty - angličtina - NLM (National Library of Medicine)

bausch health us llc - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine 20 mg - pepcid tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: pepcid tablets are indicated in adults for the: reduction of the risk of duodenal ulcer recurrence. pepcid is contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or other histamine-2 (h2) receptor antagonists. risk summary available data with h2-receptor antagonists, including famotidine, in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. in animal reproduction studies, no adverse development effects were observed with oral administration of famotidine at doses up to approximately 243 and 122 times, respectively, the recommended human dose of 80 mg per day for the treatment of erosive esophagitis (see data) . the estimated background risk for major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background ris

Spojené štáty - angličtina - NLM (National Library of Medicine)

salix pharmaceuticals, inc - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine 40 mg in 5 ml - pepcid for oral suspension is indicated in adults for the treatment of: pepcid for oral suspension is indicated in pediatric patients 1 year of age and older for the treatment of: pepcid for oral suspension is indicated in pediatric patients from birth to less than 1 year of age for the treatment of: pepcid for oral suspension is contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or other histamine-2 (h2) receptor antagonists. risk summary available data with h2-receptor antagonists, including famotidine, in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. in animal reproduction studies, no adverse development effects were observed with oral administration of famotidine at doses up to approximately 243 and 122 times, respectively, the recommended human dose of 80 mg per day for the treatment of erosive esophagitis (see data) . the estimated background ri

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

mcneil healthcare (ireland) ltd - famotidine, magnesium hydroxide, calcium carbonate - tablets chewable - milligram - h2-receptor antagonists

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

famotidine -

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

johnson & johnson (ireland) limited - famotidine; magnesium hydroxide; calcium carbonate - chewable tablet - 10/165/800 milligram(s) - h2-receptor antagonists; famotidine, combinations

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

jntl consumer health i (ireland) limited - famotidine; magnesium hydroxide; calcium carbonate - chewable tablet - h2-receptor antagonists; famotidine, combinations

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

merck sharp and dohme limited - famotidine - film coated tablet - 20 milligram

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

merck sharp and dohme limited - famotidine - film coated tablet - 40 milligram

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

mcneil healthcare (ireland) ltd - famotidine - film coated tablet - 10 milligram - h2-receptor antagonists

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

johnson & johnson (ireland) limited - famotidine - film-coated tablet - 10 milligram(s) - h2-receptor antagonists; famotidine